MINI FUTURE OPTIONSSCHEIN PUT - MODERNA | Real-time Bid/Ask 05:01:37 2024-07-16 EDT | ||
| 9.79 EUR / 9.82 EUR | -0.46% |
|
| Current month | -4.00% | ||
| 1 month | +18.96% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-07-16 | 9.79 | -0.61% |
| 24-07-15 | 9.85 | +0.41% |
| 24-07-12 | 9.81 | +1.03% |
| 24-07-11 | 9.71 | -5.45% |
| 24-07-10 | 10.27 | -1.25% |
Delayed Quote Börse Stuttgart
Last update July 16, 2024 at 05:00 am
More quotesStatic data
| Product type | Certificat Turbo Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | MODERNA, INC. |
| Issuer | DZ BANK |
| WKN | DQ3ZPJ |
| ISIN | DE000DQ3ZPJ6 |
| Date issued | 2024-05-29 |
| Strike | 228.4 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 5.61 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 10.64 € |
|---|---|
| Lowest since issue | 6.16 € |
| Spread | 0.03 € |
| Spread % | 0.31% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
121.5
USD
Average target price
145.9
USD
Spread / Average Target
+20.10%
- Stock Market
- Certificates
- Certificat
